Can a bone drug help spinal fusion patients heal stronger?
NCT ID NCT03841058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the bone-building drug abaloparatide (Tymlos) can improve healing after spinal fusion surgery. About 96 postmenopausal women and men aged 50+ will receive either the drug or a placebo daily for 6 months. Researchers will check bone fusion quality and pain levels up to one year after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Abaloparatide (Tymlos)
- What this could lead to
- If it works, this could lead to a treatment that helps bones heal better and faster after spinal fusion surgery, reducing complications like screw loosening.
- What could go wrong
- This is a small, early-phase trial with only 96 participants, so results may not apply to everyone. The drug may not improve fusion outcomes or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL FUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital for Special Surgery
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fine-tuning nerve monitoring during spine surgery could reduce injury risk
- Iron pills before scoliosis surgery may cut transfusions and boost recovery
- New study aims to take the guesswork out of spinal fusion healing
- Spine surgery's hidden toll on blood vessels revealed
- Swimming after back surgery shows promise for faster recovery
- Spine surgery pain relief: which additive works best?